Background: Alternative mRNA splicing of α i2 , a heterotrimeric G protein α subunit, has been shown to produce an additional protein, termed sα i2 . In the sα i2 splice variant, 35 novel amino acids replace the normal C-terminal 24 amino acids of α i2 . Whereas α i2 is found predominantly at cellular plasma membranes, sα i2 has been localized to intracellular Golgi membranes, and the unique 35 amino acids of sα i2 have been suggested to constitute a specific targeting signal.
Background
Heterotrimeric G proteins couple agonist-activated heptahelical receptors to a variety of effector responses. For the most part, this signaling activity takes place at the plasma membranes of cells. However, G proteins have been detected at a variety of subcellular locations and have been implicated in numerous membrane trafficking activities [1, 2] . This suggests that distinct, though not yet deter-mined, mechanisms exist to target G protein subunits to subcellular locations other than plasma membranes (PM). Furthermore, post-transcriptional or post-translational modifications may play a role in directing a G protein subunit to a specific intracellular location.
Unique subcellular localization has been observed for a novel alternative spliced form of the G protein α subunit (Gα), α i2 [3] . This α i2 splice variant, termed sα i2 , contains a novel 35 amino acid sequence that replaces the C-terminal 24 amino acids of α i2 [3] . sα i2 has been observed to localize to Golgi membranes and other intracellular membranes [3, 4] ; in contrast, wild type α i2 is typically found at PM. Based on this unique localization of sα i2 , a prominent role in membrane trafficking has been proposed for this subunit [3] . However, no report to date has supported a functional role for sα i2 in vesicular transport, although a variety of functional assays have implicated other Gα, including α s and α i3 , in vesicle trafficking pathways [1, 2] .
In spite of its unknown functional significance, sα i2 provides a potential model for studying mechanisms of subcellular localization of Gα. Clearly, some aspect of the novel splicing is responsible for the difference in subcellular targeting of sα i2 (i.e., Golgi and intracellular membranes) compared to wild type α i2 (i.e., PM). To address the mechanism of subcellular localization of sα i2 , two hypotheses were tested herein. First, the possibility was tested that the novel 35 amino acid sequence found at the Cterminus of sα i2 functions as a specific Golgi or intracellular membrane targeting motif. A second possibility was suggested by considering the location of the splice site. Several studies have shown that deletions or amino acid substitutions in the extreme C-terminal region of Gα creates a protein defective in guanine-nucleotide binding [5] [6] [7] [8] [9] [10] . Rapid release of guanine-nucleotides can result in an unstable Gα [9, 10] . This leads to the prediction that sα i2 is also unstable due to a disruption in the structure of its C-terminus caused by the novel splice sequence. Thus, the second possibility is that failure of sα i2 to localize at the PM but instead localize at intracellular membranes is the result of a general defect in protein stability. Results presented herein are consistent with this second hypothesis.
Results
α i2 and sα i2 differ only at their extreme C-termini. Alternative splicing results in a novel 35 amino acids in sα i2 that replace the C-terminal 24 amino acids of α i2 ( Figure  1 ). In the studies presented here, both α i2 and sα i2 contain an internal EE epitope, as used previously for α i2 [11, 12] . The use of the EE epitope allows the direct comparison of subcellular localization and expression of α i2 and sα i2 , and facilitates immunoprecipitation of the two expressed proteins. This is essential since suitable antibodies to detect and immuno-isolate sα i2 are not readily available. Attempts to use a previously described polyclonal antibody directed against the C-terminus of sα i2 [3, 4] were unsatisfactory in our hands. In particular, attempts to detect endogenous sα i2 by immunofluorescence failed due to faint detection that showed drastically different patterns of staining depending upon fixation technique.
The subcellular localization of expressed α i2 and sα i2 was compared in COS and BHK cells ( Figure 2 ). In both cell types, α i2 was detected at cellular plasma membranes as highlighted by bright staining at the cell periphery ( Figure  2A and 2C). In contrast, sα i2 was not detected at plasma membranes, but instead typically displayed an intracellular and perinuclear staining pattern ( Figure 2B and 2D), consistent with localization to intracellular membranes as previously described [3, 4] . The subcellular localization of sα i2 showed overlap in immunofluorescent staining with the Golgi protein, β-COP ( Figure 3A and 3B) and the endoplasmic reticulum protein PDI ( Figure 3C and 3D); localization of sα i2 exclusively to Golgi was not observed, even at the lowest levels of detection. Subcellular fractionation confirmed that sα i2 was localized, at least partly, to membranes ( Figure 2E ). After lysis of cells in hypotonic buffer followed by high-speed centrifugation, α i2 was found predominantly in the particulate fraction from COS ( Figure 2E , lanes 3 and 4) or BHK cells ( Figure 2E , lanes 9 and 10). A majority of sα i2 was also detected in the particulate fraction from both COS ( Figure 2E , lanes 5 and 6) and BHK cells ( Figure 2E , lanes 11 and 12), although some was also found in the soluble fraction. As a comparison, a non-palmitoylated mutant of α q , in which cysteines 9 and 10 have been substituted with serines, is found predominantly in the soluble fraction ( Figure 2E , lanes 7 and 8), as described previously [13] . Surprisingly, in comparison to α i2 , sα i2 was always detected in fewer cells, by immunofluorescence analysis, and showed lower levels of protein expression, by western blot analysis of subcellular fractions ( Figure 2E ) or whole cell lysates (not shown). These expression differences suggested that sα i2 was either less efficiently expressed or more rapidly degraded compared to α i2 , as described below.
The C-terminal 35 amino acids of sα i2 , which replace the C-terminal 24 amino acids of α i2 (Figure 1 ), have been proposed to function as a Golgi targeting signal [3, 4] . To test the potential importance of this C-terminal region in localization of sα i2 to intracellular membranes and prevention of sα i2 from localizing to PM, a deletion mutant of α i2 was constructed consisting of amino acids 1-331. In sα i2 , the C-terminal splice occurs just after amino acid 331 ( Figure 1) , and thus the novel 35 amino acid splice sequence is removed in α i2 . Immunofluorescence microscopy indicates that α i2 (1-331) ( Figure 4B ) displays a subcellular localization pattern very similar to sα i2 (Figure 4A ). This result is consistent with the alternative hypothesis that a disruption of α i2 at the C-terminus creates a protein unable to localize at the PM.
If the unique C-terminal 35 amino acid sequence of sα i2 functions as a Golgi targeting signal, it is important to test whether it is sufficient to target a heterologous protein to intracellular membranes. When the 35 amino acid se-quence was fused to the C-terminus of GFP (GFPsα i2 35aa), this unique sα i2 sequence failed to direct GFP to intracellular membranes ( Figure 5B ); GFP-sα i2 35aa was diffusely distributed throughout the cytoplasm and nucleus, similar to what is observed for GFP alone ( Figure  5A ). On the other hand, when the first ten amino acids of α i2 are fused to GFP to create α i2 (1-10)-GFP, fluorescence is detected strongly at the PM ( Figure 5C ), indicating the N-terminus of α i2 , which contains the sites for myristoylation and palmitoylation [14] , can be sufficient for directing PM localization of a normally cytosolic protein. In agreement with these results, the sα i2 C-terminal sequence failed to redirect the localization of a secreted or a nuclear protein [4] . Thus, not only is the unique sα i2 sequence unable to override other localization signals, it is unable to target a cytoplasmic protein to intracellular membranes. These results are consistent with a lack of a specific role for the sα i2 sequence in Golgi membrane targeting.
The above experimental results failed to support the hypothesis that the unique 35 amino acid sequence from sα i2 serves as a specific Golgi or intracellular membrane targeting motif. Thus, the following experiments concentrated on addressing the alternative hypothesis: sα i2 is unstable and rapidly degraded due to disruptions in the Cterminus, and such instability results in a failure of sα i2 to reach its proper place at the PM.
The ability of α i2 and sα i2 to undergo N-terminal lipid modifications was compared. Myristoylation occurs cotranslationally at the extreme N-terminal glycine, while palmitoylation occurs post-translationally at a cysteine immediately after the myristoylated glycine [15] . The subcellular site where palmitoylation occurs has not been well defined, although in one model palmitoylation occurs at the PM [16] . Cells expressing α i2 or sα i2 were metabolically labeled with 3 H-palmitate or 3 H-myristate. α i2 and sα i2 were immunoprecipitated from cell extracts, and incorporation of radio-label was analyzed by SDS-PAGE followed by fluorography ( Figure 6A ). No palmitoylation of sα i2 was detected ( Figure 6A , lane 3), although α i2 was strongly palmitoylated ( Figure 6A , lane 2). In contrast, both α i2 and sα i2 incorporated similar levels or myristate ( Figure 6A , lanes 5 and 6). The similar level of myristoylation was particularly surprising since total sα i2 protein was much lower than α i2 as determined by immunoblotting of the immunoprecipitates ( Figure 6B , compare lanes 5 and 6). Myristoylation is a co-translational modification, and levels of radio-labeling should thus reflect synthesis of new protein. Accordingly, the myristoylation results ( Figure 6A and 6B, lanes 5 and 6) strongly suggested that α i2 and sα i2 are translated equally well, as evidenced by similar levels of radiolabeled myristate incorporation during the labeling period, but sα i2 is more rapidly degraded, as seen by reduced steady-state levels of immunoprecipitated protein. The lack of palmitoylation of sα i2 is consistent with at least two, not necessarily mutually exclusive, possibilities. sα i2 may fail to undergo palmitoylation because it is not stable long enough for post-translational palmitoylation to occur or because it fails to reach a PM site of palmitoylation. Alternatively, the novel C-terminal sequence of sα i2 may somehow prevent direct recognition by a palmitoyl transferase.
Cells expressing high levels of sα i2 , and to a much lesser extent α i2 , often displayed very bright intracellular accumulations of sα i2 as visualized by immunofluorescence. These large spots were reminiscent of recently described aggresomes, accumulations of misfolded protein that are being targeted for proteasome-dependent degradation [17, 18] . This observation suggested the possibility that intracellular localization of sα i2 may reflect targeting to a proteasome-dependent degradative pathway. To test this idea further, cells expressing α i2 or sα i2 were treated with the proteasome inhibitor acetyl-leucyl-leucyl-norleucinal (ALLN) and changes in localization of the α subunit were analyzed by immunofluorescence ( Figure 7 ). After 1h treatment with ALLN, α i2 localization is relatively unaffected ( Figure 7C ), but sα i2 begins to show a slight increase in distinct intracellular accumulations ( Figure 7D ). At 4 h ALLN treatment, many cells expressing α i2 display a decrease in PM localization and an increase in intracellular staining ( Figure 7E ). α i2 is typically seen in large bright spots and in a perinuclear/intracellular membrane staining pattern after incubation of cells for 4 h with ALLN. In fact, the localization pattern of α i2 after 4 h incubation with ALLN ( Figure 7E ) is similar to the observed localization of sα i2 in the absence or presence of ALLN treatment ( Figure 7B , 7D, and 7F). At 8 h treatment with ALLN, both α i2 ( Figure 7G ) and sα i2 ( Figure 7H ) are detected almost exclusively as a large bright spot in each expressing cell. Similar results were obtained using another proteasome inhibitor, MG-132. Interestingly, ALLN treatment was relatively ineffective at promoting accumulation of overexpressed α s in aggresome-like structures (not shown). Thus, the results of Figure 7 are consistent with the proposal that the intracellular localization of sα i2 is due to its targeting to a degradative pathway, a pathway shared by α i2 .
The subcellular localization of sα i2 was compared to α i2 A327S. This alanine to serine mutation in the C-terminal region of α i1 (A326S) and α s (A366S) has been shown to greatly accelerate GDP release, to accelerate irreversible inactivation in vitro, and to cause rapid turnover of the α
Figure 2
Localization of α i2 and sα i2 Expression vectors encoding α i2 (A and C) or sα i2 (B and D) were transiently transfected into COS-7 (A and B) or BHK (C and D) cells. Subcellular localization of the proteins was visualized by immunofluorescence microscopy using the EE monoclonal antibody followed by a Texas Red conjugated anti-mouse antibody, as described in "Materials and Methods". Bar, 10 µm. E, pcDNA3 (lanes 1, 2), EE-α i2 -pcDNA3 (lanes 3, 4, 9, 10), EEsα i2 -pcDNA3 (lanes 5, 6, 11, 12) or EE-α q C9,10S-pcDNAI were transiently transfected into COS-7 (lanes 1-8) or BHK (lanes 9-12) cells. Cell lysates were separated into particulate (P) and soluble (S) fractions, as described in "Materials and Methods". EE-tagged Gα subunits were detected at 41-45 kDa (double asterisk) by immunoblotting with the EE monoclonal antibody. A slightly smaller protein is consistently detected (denoted by single asterisk) by the EE antibody, and this background band fractionates exclusively to the soluble fraction.
Figure 3
Localization of sα i2 to Golgi and ER membranes sα i2 was expressed in COS-7 cells. 48 h after transfection, cells on coverslips were fixed and processed for immunofluorescence. Co-localization of sα i2 (A) and the Golgi protein, β-COP (B), was visualized after incubation of cells with the EE antibody and a rabbit polyclonal anti-β-COP antibody followed by Alexa 594 anti-mouse and Alexa 488 anti-rabbit antibodies. Co-localization of sα i2 (C) and the endoplasmic reticulum protein, protein disulfide isomerase (PDI) (D), was visualized after incubation of cells with the EE antibody and a rabbit polyclonal anti-PDI antibody followed by Alexa 594 anti-mouse and Alexa 488 anti-rabbit antibodies.
subunit in cultured cells [9, 10] . Thus, if the observed intracellular localization of sα i2 is caused by instability of the protein due to disruptions at its C-terminus, then it follows that α i2 A327S should show a similar pattern of localization. Indeed, immunofluorescence microscopy revealed a pronounced intracellular distribution for α i2 A327S ( Figure 8E ). In addition to intracellular membrane localization similar to sα i2 ( Figure 8C ), α i2 A327S was detected weakly but consistently at the PM. It seems likely that the C-terminal disruption of sα i2 (replacing the 24 C-terminal amino acids) is a more severe disruption than the A327S substitution. Thus, the similarity in localization of sα i2 and α i2 A327S bolsters the idea that mislocalization of sα i2 is caused by its inherent instability.
G protein βγ subunits can stabilize wild type and alanine to serine mutant α subunits in vitro [10] . Thus, the effect of βγ co-expression on subcellular localization of α i2 A327S and sα i2 was tested. α i2 localizes to the PM efficiently when expressed alone ( Figure 8A ) or when co-expressed with βγ ( Figure 8B ). sα i2 shows a dramatic change in localization when co-expressed with βγ ( Figure 8D ), displaying strong PM staining. Not only is sα i2 targeted efficiently to the PM when co-expressed with βγ, but βγ coexpression increases overall levels of transiently expressed sα i2 and α i2 , as determined by immunoblotting ( Figure  8G ), and increases the number of cells expressing sα i2 , as observed by immunofluorescence microscopy (not shown). Similarly, co-expression of βγ efficiently promotes PM localization of α i2 A327S ( Figure 8F ).
The analysis of the effect of βγ was extended by examining the localization of α i2 or sα i2 after co-transfection with βγ and after treatment with ALLN. In contrast to Figure 7, a marked difference was observed between α i2 and sα i2 after ALLN treatment. When βγ is co-expressed with α i2 , PM localization of α i2 is observed, as shown in Figure 8B Figure  9B ). Taken together, results with βγ co-expression are consistent with the ability of βγ to promote PM targeting of Gα, and further suggest that sα i2 is less effectively stabilized than α i2 by βγ, as evidenced by ALLN-induced accumulation in intracellular aggregates ( Figure 9B ).
Figure 4
Localization of sα i2 and α i2 (1-331) Expression vectors encoding sα i2 (A) or α i2 (1-331) (B) were transiently transfected into COS-7 cells. 48 h after transfection, subcellular localization of the proteins was visualized by immunofluorescence microscopy using the EE monoclonal antibody followed by Alexa 594 anti-mouse antibody, as described in "Materials and Methods". h (E and F), or 8 h (G and H). Cells were fixed and processed for immunofluorescence using the EE antibody followed by an Alexa 488 conjugate anti-mouse antibody. Bar, 10 µm.
Figure 8
Localization of α i2 , sα i2 , and α i2 A327S and the effect of βγ Expression vectors encoding α i2 (A and B), sα i2 (C and D), or α i2 A327 (E and F) were transfected alone (A, C, and E) or together with expression vectors for β 1 and γ 2 (B, D, and F) into BHK cells. Proteins were visualized by immunofluorescence microscopy using the EE monoclonal antibody followed by an Alexa 488 conjugate anti-mouse antibody. Bar, 10 µm. G, EE-α i2 -pcDNA3 (lanes 1 and 2) or EE-sα i2 -pcDNA3 (lanes 3 and 4) were transfected into COS-7 cells alone (lanes 1 and 3) or with co-transfection of vectors encoding β 1 and γ 2 (lanes 2 and 4) . Immunoblotting with the EE antibody detected α i2 or sα i2 . Note that sα i2 expressed alone (lane 3) is very weakly detected and barely visible in this total cell lysate.
Lastly, 35 S-methionine pulse-chase labeling studies directly confirmed that sα i2 was more rapidly degraded than α i2 (Figure 10 ). After transient expression of the α subunits, cellular proteins were radiolabeled with a brief pulse of 35 S-methionine followed by a chase. Immunoprecipitation of the α subunit after increasing times of chase, followed by SDS-PAGE and fluorography revealed that radiolabeled sα i2 was rapidly lost. α i2 consistently displayed a 3-4 fold longer half-life compared to sα i2 , while α i2 A327S was intermediate. In the experiment presented in Figure 10 , the t 1/2 was determined to be approximately 90, 180, and 360 min for sα i2 , α i2 A327S, and α i2 , respectively. Although this trend was consistent, the exact t 1/2 showed some variability from experiment to experiment, probably due to varying levels of transient overexpression. It is likely that the difference in turnover of sα i2 and α i2 is even more profound when the proteins are expressed at lower levels. Consistent with this idea, sα i2 was refractory to stable expression even though cells stably expressing α i2 were easily selected (not shown). The inability to isolate cells stably expressing sα i2 can be attributed to its rapid degradation. Regardless, 35 S-methionine pulse-chase labeling studies ( Figure 10 ) demonstrate that sα i2 is indeed more rapidly degraded than α i2 .
Discussion
In addition to their well characterized role at the PM in coupling activated GPCRs to effector proteins, heterotrimeric G proteins have been implicated in a variety of other cellular functions, including membrane trafficking pathways. A splice variant of α i2 , termed sα i2 , has been proposed as a candidate to regulate vesicle transport due to its localization at intracellular membranes. The studies described in this report were undertaken to define mech-anisms that underlie subcellular localization of sα i2 . The novel 35 amino acids found in sα i2 appear not to function as a specific Golgi or endoplasmic reticulum targeting sequence. Instead, the results in this study support the proposal that sα i2 fails to target to the PM because it is an unstable protein. The following results support this hypothesis: 1) sα i2 and α i2 are equally labeled by a pulse of 3 H-myristate, although much less sα i2 protein is detected; 2) sα i2 displays a propensity to localize to potential aggresome-like structures, and this localization is greatly enhanced by proteasome inhibitor treatment; 3) the α i2 A327S mutant, previously shown to be unstable and defective in guanine-nucleotide binding, shows a similar pattern of subcellular localization (i.e., intracellular membranes rather than PM); 4) βγ over-expression increases
Figure 9
Effect of ALLN on α i2 and sα i2 localization when coexpressed with βγ Expression vectors encoding α i2 (A) or sα i2 (B) were transfected together with expression vectors for β 1 and γ 2 into BHK cells. 48 h after transfections cells were incubated in the presence of 20 µg/ml ALLN for 8 h. Cells were fixed and processed for immunofluorescence using the EE antibody followed by an Alexa 594 conjugate anti-mouse antibody. Bar, 10 µm.
Figure 10
Pulse-chase analysis of α i2 , sα i2 , and α i2 A327S Expression vectors encoding α i2 , sα i2 , or α i2 A327 were transfected into COS-7 cells. 48 h after transfection, cells were incubated for 10 min in media containing 0.1 mCi/ml 35 S Express protein labeling mix. Cells were washed, and incubated in regular media for the indicated times (chase). Cells were harvested, lysates were prepared, and immunoprecipitations were performed using the EE antibody. Samples were resolved by SDS-PAGE, and radiolabeled proteins were visualized by fluorography (upper panel). Note that two bands are present in the sα i2 lanes; the upper band represents fulllength sα i2 and quantitation of this band was used to determine a half-life. The lower band likely represents a degradation product of sα i2 that is itself degraded even faster. Quantitation of the bands from the fluorograph was performed by densitometry and plotted as degradation curves (lower panel) for α i2 ('), sα i2 (O), and α i2 A327 (∇). These experiments were repeated and the average ± S.E. half-life was determined as 237 ± 110, 150 ± 42, and 67 ± 21 min for α i2 (n = 3), α i2 A327 (n = 2), and sα i2 (n = 3), respectively.
expression of sα i2 and promotes PM localization of sα i2 and α i2 A327S, but βγ co-expression does not prevent sα i2 localization to potential aggresome-like structures when cells are treated with proteasome inhibitors; and 5) pulsechase analysis indicates that sα i2 is rapidly degraded.
A number of reports have demonstrated that disruptions in the C-termini of Gα cause reduced affinity for guaninenucleotides and protein instability. The C-terminal 30 amino acids of Gα consist of the β6-α5 loop, followed by the α5 helix and finally several amino acids of flexible structure (Figure 1 ) [19] [20] [21] . The β6-α5 loop stabilizes the guanine ring of bound GDP or GTP, and mutations in this region affect guanine-nucleotide binding. The A326S mutation of α i1 and A366S mutation of α s (cognate to the α i2 A327S used in this study) were shown to cause greatly decreased affinity for GDP [9, 10] . Defective binding of GDP leads to more Gα in the empty state (no bound guanine-nucleotide), and this form of Gα is rapidly denatured in vitro, as shown for α s A366S and α i1 A326S [9, 10] . Moreover, α s A366S was demonstrated to undergo rapid degradation (t 1/2 < 1 h) in stably transfected cells [9] . The same mutation in α t has also been shown to greatly decrease guanine-nucleotide binding [5, 22] . Additional amino acids in the critical β6-α5 loop are important for maintaining Gα integrity [7] .
Although the α5 helix (Figure 1) does not directly contact the bound guanine-nucleotide [19] [20] [21] , it is clearly important for Gα structure and to maintain the proper orientation of the β6-α5 loop. A recent study identified a number of α5 helix residues in α t that when changed to alanines increased rates of guanine-nucleotide exchange (i.e., decreased affinity for guanine-nucleotides) [5] . Individual mutation of amino acids in α t , cognate to T330, N332, V333, F337 in α i2 (Figure 1) , increased nucleotide exchange rates [5] . Two of these critical amino acids, N332 and V333 in α i2 , are in fact the first two amino acids that are replaced by the novel splicing in sα i2 (Figure 1 ). Thus, one might speculate that the novel 35 amino acid sequence in sα i2 would impair guanine-nucleotide binding and result in a unstable protein. Unfortunately, initial attempts to directly show a defect in guanine-nucleotide binding by sα i2 , using a GTPγ S-dependent trypsin protection assay [23] , were unsuccessful due, at least in part, to the inability to solubilize expressed sα i2 from membranes using a mild detergent (e.g., lubrol/polyoxyethylene 10lauryl ether).
The data in this report are consistent with a scenario in which intracellular Golgi/ER localization of sα i2 reflects its rapid degradation rather than specific targeting to a subcellular organelle. Particularly compelling is the similarity in subcellular localization of α i2 A327S and sα i2 (Figure 8 ). In addition, the use of proteasome inhibitors ( Figures 7 and 9 ) suggest that sα i2 is degraded by a proteasome pathway. The observed intracellular membrane (ER) localization and proteasome inhibitor-induced juxtanuclear aggregate accumulation (aggresome) is consistent with that reported for other proteins being degraded by such a pathway [18, 24] . When treated with proteasome inhibitors, overexpressed wild type α i2 also accumulates in aggresome-like structures (Figure 7 ), suggesting that Gα may normally be degraded by a proteasome-dependent pathway. However, over-expression of βγ prevents ALLNinduced juxtanuclear accumulations of α i2 but not sα i2 (Figure 9 ). Although little is known regarding degradative pathways for G proteins, sα i2 and other mutants (e.g., α i2 A327S) may be valuable tools for defining such pathways.
The data presented here argue against a sequence specific Golgi membrane targeting function for the novel 35 amino acid sequence found in sα i2 . The novel sequence of sα i2 is not sufficient to direct other proteins to Golgi/ER membranes. These 35 amino acids did not change the cytoplasmic localization of GFP ( Figure 5 ). Similarly, a recent report showed that the sα i2 35 amino acids were unable to retain a secreted protein in intracellular membranes and did not affect localization of a nuclear protein [4] . However, in addition to causing rapid degradation, one cannot rule out that the 35 amino acid sequence of sα i2 functions somehow as part of a Golgi targeting motif in the context of other regions of α i2 , as suggested [4] .
Other researchers have described a specific Golgi membrane localization of sα i2 [4] ; in contrast, the results presented in this report always show a much more disperse subcellular localization of sα i2 to intracellular membranes consistent with staining of both Golgi and ER. The reason for this difference in localization is unclear. Interestingly, in the other study, the authors found that deletion of a proline-rich sequence corresponding to sα i2 amino acids 348-359 ( Figure 1 ) changed localization of sα i2 from Golgi membranes to a more diffuse localization throughout intracellular membranes [4] . However, mutation of proline residues to alanines failed to affect sα i2 localization [4] . Thus, little evidence exists to support a specific membrane targeting role for the novel sα i2 sequence.
βγ was able to promote plasma membrane localization of sα i2 (Figure 8 ). βγ prevents irreversible inactivation of α i1 , when measured in vitro at 37°C, and slows the inactivation of α i1 A326S [10] . Thus, βγ may stabilize sα i2 and α i2 A327S allowing βγ-dependent [25] [26] [27] [28] [29] PM localization. These results are also consistent with the possibility that the primary defect in sα i2 is a reduced ability to interact with βγ; Gα containing mutations in known sites of contact with βγ fail to localize to PM, but over-expression of βγ can rescue their PM localization [28, 29] . However, the crystal structures [30, 31] show that the C-terminal β6-α5 loop/α5 helix region does not directly contact βγ. Thus, it is more likely that indeed sα i2 is deficient in binding to βγ, but this effect is a consequence of its instability. sα i2 may exist in a state that does not interact well with βγ simply because it is in the process of being irreversibly inactivated [9, 10] . Similarly, α i2 A327S appears not to be defective in its intrinsic ability to interact βγ [10] , and coexpression of βγ shifts α i2 A327S, like sα i2 , from intracellular to plasma membranes (Figure 8) .
What is the cellular function of sα i2 ? The ability of βγ to promote PM localization of sα i2 raises the possibility that endogenous sα i2 is in fact localized to PM where it can interact with GPCRs and effectors. Future studies will test the potential of sα i2 , when co-expressed with βγ, to productively interact with receptors and effectors. However, this possibility is viewed as unlikely for several reasons. First, others have shown that in COS-7 cells endogenous sα i2 is not detected at PM but only found intracellularly [3, 4] , although one cannot rule out that a small but functionally significant fraction of sα i2 reaches the PM. Second, the extreme C-termini of Gα are critical sites for interaction with GPCRs [32] , and the novel C-terminal sequence found in sα i2 would be predicted to disrupt productive interactions with GPCRs. Third, even though βγ can promote PM localization of sα i2 in the overexpression system described here, sα i2 remains less stable than α i2 (Figure 9 ), suggesting that such instability may also impair productive interactions with GPCRs.
On the other hand, unknown protein(s) may function to stabilize sα i2 and help direct it to Golgi membranes. A specific combination of β and γ subtypes may play such a role; however, one thorough study showed a lack of βγ on Golgi membranes of exocrine pancreatic cells even though a variety of Gα were readily detected in the Golgi [33] . Other proteins that may specifically promote the intracellular targeting of Gα have not been identified.
It is possible that sα i2 functions as a short-lived protein regulating some aspect of membrane transport pathways; however, no experiments to directly support or refute this hypothesis have been reported. Instead, it is tempting to speculate that alternative splicing may be a mechanism to regulate cellular levels of α i2 . In this model, certain conditions may favor the formation of sα i2 compared to α i2 , and the resulting rapid degradation of sα i2 would decrease the cellular content of α i2 . A precedent for such alternative splicing-dependent regulation of expression has been described for H-ras [34] . Alternative splicing occurs in H-ras, and the alternative spliced form is predicted to encode an unstable transcript and a protein product that lacks the ability to oncogenically transform cells. A mutation was identified that abolishes the alternatively spliced form, and this mutation leads to an increase in H-ras expression and transforming ability. Thus, it was demonstrated that alternative splicing is a mechanism that cells use to control expression of H-ras [34] . Alternative splicing may similarly play an important role in regulating expression of α i2 . Testing of this idea will require a comparison of sα i2 and α i2 transcript levels, and an analysis of whether relative expression is affected in response to physiological changes, such as extracellular stimuli or cell differentiation.
Conclusions
In summary, the results presented here demonstrate that sα i2 , a novel splice variant of α i2 , is rapidly degraded when expressed in cells. Such instability is consistent with known structure-function data regarding the importance of the C-terminus of Gα subunits. The observed intracellular localization of sα i2 is due, at least in part, to its instability. Moreover, the data presented in this study argue against the novel C-terminus of sα i2 functioning as a specific Golgi targeting motif.
In addition, similarly to sα i2 , an α i2 mutant, α i2 A327S, previously demonstrated to be unstable in vitro, displays a defect in plasma membrane localization when expressed in cells. These results suggest that both sα i2 and α i2 A327S may prove valuable in future studies of mechanisms of degradation of Gα.
Materials and methods

Materials
Cell culture reagents were obtained from Mediatech.
[9,10-3 H]palmitic acid, [9,10-3 H]myristic acid, and 35 S Express labeling mix were from NEN. Acetyl-leucyl-leucylnorleucinal (ALLN) and MG-132 were from Calbiochem. The EE monoclonal antibody was a gift from H. Bourne. Other reagents were obtained from Fisher and Sigma.
Expression plasmids
EE-α i2 -pcDNAI was obtained from H. Bourne (UCSF). In this plasmid, mouse α i2 cDNA contains the EE epitope sequence EEYMPTE at codons 166 to 172 [11] . Mouse sα i2 cDNA was provided by E. Borrelli (Strasbourg) in the plasmid pSVsGi2. sα i2 was excised from pSVsGi2 using EcoRI and SmaI and subcloned into the EcoRI and EcoRV sites of pcDNAI to produce sα i2 -pcDNAI. EE-tagged sα i2 was constructed by subcloning a EcoRI-BglII fragment from EE-α i2 -pcDNAI into sα i2 -pcDNAI. EE-tagged α i2 A327S-pcDNAI was obtained from J. Morales (UCSF). EE-tagged α i2 (1-331)-pcDNA3 was constructed by by PCR amplification of the coding region for the amino acids 1 to 331 of α i2 using the T7 primer as the 5' primer and 5'-ccggctcgagtcacttggtgtcggtggcgcatg-3' as the 3' primer and using EE-α i2 -pcDNA3 as the template. The PCR amplified product was digested with HindIII and XhoI and subcloned into the correspondingly digested EE-α i2 -pcDNA3. GFPsα i2 35aa was constructed by PCR amplification of the coding region for the C-terminal 35 amino acids of sα i2 using the 5' primer 5'-cgcagatctagaaaactttttaga-3' and the 3' primer 5'-cgcaagcttactcaaggcacggaatc-3'. The PCR fragment was digested with BglII and HindIII and subcloned into the correspondingly digested pEGFP-C1 (Clontech). α i2 (1-10)-GFP was constructed by annealing the complementary oligonucleotides 5'-ctagcaccatgggctgcaccgtgtcggccgaggacaag-3' and 5'ccggcttgtcctcggacacggtgcagcccatggtg-3' (corresponding to amino acids 1-10 of α i2 ) and ligating into AgeI-NheI digested pEGFP-N1. Human β 1 -pCMV5 and bovine γ 2 -pcD-NAI have been described [35] .
Cell culture and transfection BHK, HEK293, and COS-7 cells were cultured in DMEM containing 10% fetal bovine serum. Transfections were performed in 6-well plates or 6 cm culture dishes using Lipofectamine (GibcoBRL) or FuGene6 (Roche) according to the manufacturer's protocol.
Immunofluorescence localization
Cells were transfected in 6-well plates with 1 µg of the indicated expression plasmid. In experiments where β 1 and γ 2 expression plasmids were co-transfected with α i2 or sα i2 , the amounts of α, β, and γ plasmids used were 0.7, 0.2, and 0.1 µg, respectively. 24 h after transfection, cells were replated onto glass coverslips and grown for an additional 24 h before fixing in methanol at -20°C for 20 min. Cells were washed with PBS and then incubated in blocking buffer consisting of TBS (50 mM Tris, pH 7.5, 150 mM NaCl) with 1% Triton X-100 and 2.5% nonfat milk. Coverslips were then incubated in blocking buffer containing 20 µg/ml EE monoclonal antibody for 1 h. For dual localization experiments, a 1:1000 dilution of a rabbit polyclonal anti-β-coatomer protein (β-COP) antibody (Affinity BioReagents) or a 1:200 dilution of a rabbit polyclonal anti-protein disulfide isomerase (PDI) antibody (Stress-Gen Biotechnologies) was included with the EE mouse monoclonal. Following washes with blocking buffer, cells were incubated in a 1:100 dilution of the indicated secondary antibody, either Alexa Fluor 488 or 594 goat antimouse (Molecular Probes) or Texas Red donkey antimouse (Jackson Immunoresearch) or Alexa Fluor 488 goat anti-rabbit (Molecular Probes), for 30 min. The coverslips were washed and mounted on glass slides with Prolong Antifade reagent (Molecular Probes, Eugene, OR), and microscopy was performed with an Olympus BX60 microscope equipped with a Sony DKC-5000 digital camera. A minimum of 50 cells were examined for each transfection. Transfections were repeated and representative pictures were taken of cells displaying a typical expression pattern for each transfection. Only cells displaying low to intermediate levels of expression were utilized. Images were processed with Adobe Photoshop.
Subcellular Fractionation
Soluble and particulate fractions were isolated as previously described [29] . BHK or COS-7 cells were transfected in 6 cm plates with 3 µg of the indicated expression plasmid. 24 h after transfection, the cells were transferred to 10-cm plates and grown for another 24 h. Cells were washed with phosphate-buffered saline and then lysed in 0.5 ml hypotonic lysis buffer by 10 passages through a 27gauge needle. Cells were centrifuged at 200 × g for 5 min to pellet nuclei and intact cells, and the supernatant was then centrifuged at 150,000 × g for 20 min to obtain soluble and particulate fractions. Fractions were resolved by 12% SDS-PAGE, transferred onto PVDF-Plus (Micron Separations, Inc) and probed with EE monoclonal antibody. Bands were visualized by chemiluminescence.
Metabolic labeling and immunoprecipitation
COS-7 cells were transfected in 6 cm plates with 3 µg of the indicated expression plasmid. 24 h after transfection, cells were replated into 6 cm plates. For fatty acid labeling experiments [36] , one transfection was replated into two 6 cm plates. For 35 S labeling experiments, cells from two or three identical transfections were combined before replating in multiple 6 cm plates. Incubation with radioisotope was then performed 48 h after transfection.
For fatty acid labeling, cells in a 6 cm dish were incubated with 1 ml of DMEM containing 10% dialyzed fetal bovine serum, 5 mM sodium pyruvate, and [9,10-3 H]palmitic acid (1 mCi/ml) or [9,10-3 H]myristate (0.5 mCi/ml) for 2 h. For 35 S pulse-chase labeling, cells in a 6 cm dish were washed with DMEM (without methionine), and then incubated in DMEM (without methionine) containing 10% dialyzed fetal bovine serum at 37°C for 1 h. Next, cells were incubated in DMEM (without methionine) containing 10% dialyzed fetal bovine serum and 0.1 mCi/ml 35 S Express mix for 10 min. After the 10 min pulse labeling, cells were either immediately lysed (see below) or washed with normal growth media and then "chased" by incubation in normal growth media for the indicated times.
Fatty acid labeled and 35 S methionine/cysteine labeled samples were then identically processed by immunoprecipitation. Cells were washed once with ice-cold PBS and lysed in 1 ml of Extraction buffer (50 mM HEPES, pH 8, 50 mM NaCl, 10 µM β-mercaptoethanol, 1% Triton X-100, 1% sodium cholate, 1 mM PMSF, 2 µg/ml leupeptin, and 2 µg/ml aprotinin). Cell extracts were tumbled for 1 h at 4°C, and nuclei and insoluble material were removed by microcentrifugation at 16,000 × g for 3 min. Samples were adjusted to 0.5% SDS. 10 µg of EE antibody was added, and the samples were tumbled for 2 h at 4°C. Next, 20 µl of Protein A/G PLUS agarose (Santa Cruz Biotechnology, Santa Cruz, CA) was added, and the sample was tumbled overnight at 4°C. The sample was centrifuged for 30 s at 200 × g to pellet the beads. The supernatant was discarded, and the beads were washed 3 times with 1 ml Extraction buffer. SDS-PAGE sample buffer containing 10 mM DTT was added to the washed beads, and the samples were heated at 65°C for 1 min ( 3 H fatty acid labeled samples) or boiled for 5 min ( 35 S methionine/cysteine labeled samples). An aliquot was analyzed by 10% SDS-PAGE. Gels were incubated for 20 min in an aqueous solution of 50% methanol/10% acetic acid, followed by 10% ethanol/10% acetic acid for 20 min, and, finally, Amplify (Amersham) for 20 min. Gels were dried and subjected to fluorography at -80°C using Hyperfilm MP (Amersham). For 35 S pulse-chase experiments, intensity of each labeled band was quantitated by densitometry. Results were analyzed with GraphPad Prizm software to determine a half-life.
